Common but poorly defined heterogeneous diseases like dry AMD and linked diseases affect millions of people around the world. Through a deeper understanding of disease, we have identified dozens of therapeutic candidates for indications within AMD and linked diseases and are conducting natural history studies that will help us to define the populations for the first of our therapeutic candidates.
We are using genetics to select our targets and our biology to define our approach and choose the appropriate modalities to create the best therapeutic candidates. Our deep pipeline spans multiple genetically defined targets and uses the most appropriate modalities including recombinant proteins, monoclonal antibodies, and gene therapies.
Our Development Programs
We are currently engaged in preclinical development activities for multiple therapeutic candidates in distinct genetically defined AMD and linked disorders.